



1st INTERNATIONAL **GENITOURINARYCANCER** HYBRIDCONFERENCE (IGCC)

SCIENTIFIC PROGRAM



FRIDAY, 5 NOVEMBER 2021

MORNING SESSION

Chairpersons: Dr. Ashraf Abusamra, Dr. Majid Aljahel

TIME	TOPIC	SPEAKER
09:00 - 09:10 am	Welcome Address Speaker's Welcome & Introduction	Dr. Mubarak Al Mansour Chairman, 1 st IGCC Session Moderators
09:10 - 09:20 am	A phase 3 trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): Overall survival with abiraterone acetate plus prednisone in PEACE-1	Dr. Abdurhaheem Alshangiti
09:20 - 09:30 am	Health -related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration -resistant prostate cancer	Dr. Adnan Hussein
09:30 - 09:40 am	A phase 3, randomized, double-blind, placebo-control study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer	Dr. Samir Alfotihled
09:40 - 09:50 am	Discussion: Panel Question & Answer	
09:50 - 10:20 am	"Advances in the management of mHSPC"	Dr. Neeraj Agarwal
10:20 - 10:30 am	Coffee /Tea Break	
10:30 - 11:00 am	"Fundamental Role of ADT in Advanced Prostate Cancer"	Dr. Fred Saad
11:00 - 11:10 am	Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)	Dr. Bassam Basulaiman
11:10 - 11:20 am	STAR. A Randomized Multi-Stage Phase II/III Trial of Standard First-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the Treatment of Locally Advanced and/or Metastatic Renal Cancer (RCC)	Dr. Roula Mufti
11:20- 11:30 am	Discussion: Panel Question & Answer	
11:30 - 12:00 pm	"From Trial to Practice: Role of Nivo + Ipi combination in the treatment of 1L aRCC"	Dr. Shadi Alkhayyat
12:00 - 02:00 pm	Closing Remarks... Prayer and Lunch Break	

FRIDAY, 5 NOVEMBER 2021

AFTERNOON SESSION

TIME	TOPIC	SPEAKER
02:00 – 02:10 pm	Welcome Address	Dr. Mubarak Al Mansour Chairman, 1 st IGCC
	Speaker's Welcome & Introduction	Session Moderators
SESSION 1: PROSTATE CANCER		
Chairpersons : Dr. Abdullah Alsharm, Dr. Faisal Azam, Dr. Shouki Bazarbashi		
02:10 – 02:30 pm	Update on Management M1 CSPC	Dr. Karim Fizazi
02:30 – 02:40 pm	Discussion: Panel Question & Answer	
02:40 – 03:00 pm	Updates on the Management of Metastatic Castration Resistant Prostate Cancer	Dr. Maha Hussain
03:00 – 03:10 pm	Discussion: Panel Question & Answer	
03:10 – 03:30 pm	Novel surface protein targeting therapies: PSMA and beyond	Dr. Fred Saad
03:30 – 03:40 pm	Discussion: Panel Question & Answer	
03:40 – 04:00 pm	Prayer Break	
04:00 – 04:20 pm	Personalized management: DNA repair deficiency, germ line and somatic tumor testing, challenges and results	Dr. Kim Chi
04:20 – 04:30 pm	Discussion: Panel Question & Answer	
SESSION 2: RENAL CELL CARCINOMA		
Chairpersons : Dr. Esam Murshid, Dr. Fahad Ibnshamsah, Dr. Hulayel Alharbi		
04:30 – 04:50 pm	Adjuvant therapy: is Disease-free survival enough?	Dr. Daniel Heng
04:50 – 05:00 pm	Discussion: Panel Question & Answer	
05:00 – 05:20 pm	First line therapy: Latest Development	Dr. Brian Rini
05:20 – 05:30 pm	Discussion: Panel Question & Answer	
05:30 – 05:50 pm	Sequencing in MRCC	Dr. Camillo Porta
05:50 – 06:00 pm	Discussion: Panel Question & Answer	
06:00 – 06:20 pm	Prayer Break	
06:20 – 06:40 pm	Cytoreductive nephrectomy upfront or delayed: Is there a role?	Dr. Daniel Heng
06:40 – 06:50 pm	Discussion: Panel Question & Answer	
06:50 – 07:10 pm	Non-clear cell RCC: Is there a role for Immunotherapy	Dr. Sumantal Monty Pal
07:10 – 07:20 pm	Discussion: Panel Question & Answer	
07:20 – 07:50 pm	“Advances in Prostate Cancer Management: Quantifying Clinical Outcomes in mCSP”	Dr. Neal D. Shore
07:50 pm	Wrap-up and Closing	Session Moderators & Chairman

SATURDAY, 6 NOVEMBER 2021

MORNING SESSION

Chairpersons : Dr. Mohammed Baghdadi, Dr. Nedal Bukhari

TIME	TOPIC	SPEAKER
09:00 - 09:10 am	Welcome Address	Dr. Mubarak Al Mansour Chairman, 1 st IGCC Session Moderators
	Speaker's Welcome & Introduction	
09:10 – 09:20 am	Pembrolizumab vs Placebo as Adjuvant Therapy for Patients with Renal Cell Carcinoma: Patient-Reported Outcomes in KEYNOTE-564	Dr. Faisal Albadainah
09:20 – 09:30 am	Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: a randomized phase II trial (PRISM)	Dr. Marwan Al-hajeili
09:30 – 09:40 am	Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic or Locally Advanced Urothelial Carcinoma and Fibroblast Growth Factor Receptor Alterations: First Results From the Phase 2 NORSE Stud	Dr. Saeed Bamousa
09:40 – 09:50 am	Discussion: Panel Question & Answer	
09:50 – 10:20 am	“Applying comprehensive geriatric assessment in UC patients for precise management case presentation”	Dr. Fahad Almugbel
10:20 – 10:30 am	Coffee /Tea Break	
10:30 – 11:00 am	“Role Of TKI in mRCC Management”	Dr. Roula Mufti
11:00 – 11:10 am	Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)	Dr. Mohammed Alghamdi
11:10 – 11:20 am	Dose dense methotrexate, vinblastine, Doxorubicine and cisplatin (dd-mvac) or Gemcitabine and cisplatin (gc) as peri Operative chemotherapy for patients With muscle invasive bladder cancer	Dr. Amin Eltigani
11:20– 11:30 am	Discussion: Panel Question & Answer	
11:30 – 12:00 pm	“Role of IO in 1L RCC Management”	Dr. Faisal Azam
12:00 – 02:00 pm	Closing Remarks... Prayer and Lunch Break....	

SATURDAY, 6 NOVEMBER 2021

AFTERNOON SESSION

TIME	TOPIC	SPEAKER
01:30 – 01:50 pm	"Role of Cabozantinib after Progression on 1L treatments in aRCC"	Dr. Guillermo De Velasco
02:00 – 02:10 pm	Welcome Address	Dr. Mubarak Al Mansour
	Speaker's Welcome & Introduction	Chairman, 1 st IGCC Session Moderators
SESSION 3: BLADDER CANCER		
Chairpersons : Dr. Emad Taskhandi, Prof. Jamal Zekri, Dr. Saeed Bamoussa		
02:10 – 02:30 pm	Bladder cancer genomics: How to interpret the results	Dr. Bishoy Morris Faltas
02:30 – 02:40 pm	Discussion: Panel Question & Answer	
02:40 – 03:00 pm	Adjuvant therapy: is IO now the standard?	Dr. Joseph Kim
03:00 – 03:10 pm	Discussion: Panel Question & Answer	
03:10 – 03:30 pm	Maintenance Theory in Metastatic Urothelial	Dr. Thomas Powles
03:30 – 03:40 pm	Discussion: Panel Question & Answer	
03:40 – 04:00 pm	Prayer Break	
04:00 – 04:20 pm	Sequencing of current treatments	Dr. Fernando Sabino
04:20 – 04:30 pm	Discussion: Panel Question & Answer	
04:30 – 04:50 pm	Novel treatments: Antibody-drug conjugates / FGFR inhibitors	Dr. Shilpa Gupta
04:50 – 05:00 pm	Discussion: Panel Question & Answer	
SESSION 4: TESTICULAR CANCER		
Chairpersons : Dr. Shadi Alkhayyat, Dr. Sultan Alkhateeb		
05:00 – 05:20 pm	Management of poor risk disease	Dr. Christian Kollmannsberger
05:20 – 05:30 pm	Discussion: Panel Question & Answer	
05:30 – 05:50 pm	Second line therapy: Is high dose chemotherapy the standard of care?	Dr. Christian Kollmannsberger
05:50 – 06:00 pm	Discussion: Panel Question & Answer	
06:00 pm	Wrap-up and Closing	Session Moderators & Chairman

1st

INTERNATIONAL GENITOURINARYCANCER HYBRIDCONFERENCE (IGCC)

SPONSORS

AstraZeneca  Pfizer  astellas 

janssen 

 MSD
INVENTING FOR LIFE

MERCK  IPSEN
Innovation for patient care

AMGEN



LIVE Events Organizer
PRESENTATION

شركة العرض المباشر لتنظيم المعارض والمؤتمرات